For Residents

Treatment of Actinic Keratoses

Much of a dermatologist's career will be spent treating actinic keratoses (AKs). Cryotherapy is the mainstay treatment of AK, and for most clinicians it is the de facto treatment of individual lesions. Topical therapies are highly utilized alternatives to cryotherapy with numerous agents now approved by the US Food and Drug Administration. No treatment algorithm currently exists for first-line or second-line therapies due to a lack of comparative studies, which makes it challenging to identify which treatment is best for an individual patient. This article reviews the most relevant comparative studies with a focus on treatment efficacy. The author also presents her approach to the use of these medications.


 

Recommended Reading

'Early, Proactive' Management of Chemo Toxicites Improves QOL
MDedge Dermatology
Numbing Agents Cause More Pain in PDT
MDedge Dermatology
Study Results Support Ingenol Mebutate's AK Effectiveness
MDedge Dermatology
Economic Forecast: Rough Road Ahead for Dermatologists
MDedge Dermatology
RUC Predicted to Slash AK Reimbursement
MDedge Dermatology
Photodamage Effectively Treated With Quasi-Ablative Approach
MDedge Dermatology
BRAF-Plus-MEK Inhibition Slows Melanoma
MDedge Dermatology
What Is the Role of Field-Directed Therapy in the Treatment of Actinic Keratosis? Part 1: Overview and Investigational Topical Agents
MDedge Dermatology
What Is the Role of Field-Directed Therapy in the Treatment of Actinic Keratosis? Part 2: Commonly Used Field-Directed and Lesion-Directed Therapies
MDedge Dermatology
Cosmetic Clinical Indications for Photodynamic Therapy
MDedge Dermatology